Conor Hinchey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Conor Hinchey has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aisha Saldanha
Dana-Farber Cancer Institute, Boston, Massachusetts
30 shared publications - Bishma Tuladhar
Dana-Farber Cancer Institute, Boston, Massachusetts
30 shared publications - Cloud P. Paweletz
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
30 shared publications - David Allen Barbie
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
30 shared publications - Elena V. Ivanova
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
30 shared publications - Elliott Joseph Brea
Dana-Farber Cancer Institute 3 Lowe Center for Thoracic Oncology Harvard Medical School, Boston, Massachusetts
30 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Enrichment in embryonic epithelial signatures in osimertinib vs vehicle treated mice from Figure 1D.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Enrichment in embryonic epithelial signatures in osimertinib vs vehicle treated mice from Figure 1D.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Confirmation of TROP2 overexpression in surgical samples (n = 5 lobectomy, n = 1 pneumonectomy) of EGFR-mutant NSCLC after treatment with erlotinib, gefitinib or afatinib.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Confirmation of TROP2 overexpression in surgical samples (n = 5 lobectomy, n = 1 pneumonectomy) of EGFR-mutant NSCLC after treatment with erlotinib, gefitinib or afatinib.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Radiographic responses of Patients #2, #3 and #4.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Radiographic responses of Patients #2, #3 and #4.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Clinical characteristics of patients with EGFR-mutant NSCLC who received neoadjuvant EGFR-TKI followed by surgical resection.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Clinical characteristics of patients with EGFR-mutant NSCLC who received neoadjuvant EGFR-TKI followed by surgical resection.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TACSTD2 sequencing, hematoxylin and eosin staining and TROP2 IHC from in vivo relapsed tumors shown in Figure 4C in the sacituzumab govitecan group and the TROP2 CAR-T group.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TACSTD2 sequencing, hematoxylin and eosin staining and TROP2 IHC from in vivo relapsed tumors shown in Figure 4C in the sacituzumab govitecan group and the TROP2 CAR-T group.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TROP2 expression does not modulate osimertinib sensitivity and is not required for osimertinib DTP survival.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TROP2 expression does not modulate osimertinib sensitivity and is not required for osimertinib DTP survival.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure_S12 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S12. In vivo kinetics of CAR infiltration into PC9 subcutaneous tumor. PC9 tumors once established at ∼100 mm3 were injected with either 2.5E6 irrelevantly targeted control or TROP2 CAR+ cells expressing NanoLuciferase, which allows for in vivo tracking of CAR. Mice were imaged after injecting with FFz substrate at indicated time points post CAR engraftment, with right flank representing PC9 mCRD and left flank PC9 mCPD tumor inoculation site.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure_S12 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S12. In vivo kinetics of CAR infiltration into PC9 subcutaneous tumor. PC9 tumors once established at ∼100 mm3 were injected with either 2.5E6 irrelevantly targeted control or TROP2 CAR+ cells expressing NanoLuciferase, which allows for in vivo tracking of CAR. Mice were imaged after injecting with FFz substrate at indicated time points post CAR engraftment, with right flank representing PC9 mCRD and left flank PC9 mCPD tumor inoculation site.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure_S4 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S4. Activity of TROP2 VH based CAR against PC9 and HCC827GR6. A. Viability of benchmark hRS7-based CAR and novel TROP2 VH CAR binders against PC9. Cytotoxicity performed at E:T of 1:1 with coincubation for 24 h. Assessed for cytotoxicity via luminescence-based cytotoxicity. Viability reported relative to control irrelevant BCMA CAR. B. Viability of benchmark hRS7-based CAR and novel TROP2 VH CAR against HCC827GR6. Cytotoxicity performed at E:T of 1:1 with coincubation for 24 h. Assessed for cytotoxicity via luminescence-based cytotoxicity. Viability reported relative to irrelevantly targeted control CAR. P values reported as follows compared to control: ns, P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure_S4 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S4. Activity of TROP2 VH based CAR against PC9 and HCC827GR6. A. Viability of benchmark hRS7-based CAR and novel TROP2 VH CAR binders against PC9. Cytotoxicity performed at E:T of 1:1 with coincubation for 24 h. Assessed for cytotoxicity via luminescence-based cytotoxicity. Viability reported relative to control irrelevant BCMA CAR. B. Viability of benchmark hRS7-based CAR and novel TROP2 VH CAR against HCC827GR6. Cytotoxicity performed at E:T of 1:1 with coincubation for 24 h. Assessed for cytotoxicity via luminescence-based cytotoxicity. Viability reported relative to irrelevantly targeted control CAR. P values reported as follows compared to control: ns, P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure_S13 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S13. Body weight monitoring of mice treated with CAR T cells. Mice bearing PC9 CPD or CRD tumors were treated with various TROP2 CAR T or control irrelevantly targeted control CAR T cells at a dose of 2.5E6 CAR+ via i.v., and body weights were measured at indicated time points to assess treatment-related toxicity. Data are presented as mean ± SEM. Two-way ANOVA showed no significant differences in body weight between treatment groups and the control CD19 CAR groups.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure_S13 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S13. Body weight monitoring of mice treated with CAR T cells. Mice bearing PC9 CPD or CRD tumors were treated with various TROP2 CAR T or control irrelevantly targeted control CAR T cells at a dose of 2.5E6 CAR+ via i.v., and body weights were measured at indicated time points to assess treatment-related toxicity. Data are presented as mean ± SEM. Two-way ANOVA showed no significant differences in body weight between treatment groups and the control CD19 CAR groups.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure_S11 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S11. In vitro live-cell imaging of PC9 WT treated with various TROP2 CAR constructs. In vitro activity in live-cell imaging assay of TROP2 CARs against PC9 WT. PC9 was transduced with GFP and live-cell imaging performed on Incucyte with counting of green objects. Cytotoxicity index is green cell object count relative to t = 0 when CARs were applied at E:T of 0.25:1. Data are representative of multiple independent experiments with different donors.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure_S11 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Figure S11. In vitro live-cell imaging of PC9 WT treated with various TROP2 CAR constructs. In vitro activity in live-cell imaging assay of TROP2 CARs against PC9 WT. PC9 was transduced with GFP and live-cell imaging performed on Incucyte with counting of green objects. Cytotoxicity index is green cell object count relative to t = 0 when CARs were applied at E:T of 0.25:1. Data are representative of multiple independent experiments with different donors.